Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- List of variants from targeted analysis of selected gene panels
Study Overview
Brief Summary
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation. Such liver bypass can cause several health problems, one of the most severe being portopulmonary hypertension (PoPH).
The goal of this study is to identify pathogenic and potentially pathogenic genetic variants in patients who have both CPSS and PoPH. Future research will assess the contribution of these genetic variants to the development of PoPH.
The long-term goal is to use genetic information to identify patients with congenital portosystemic shunts (CPSS) or chronic liver disease who are at risk of developing PoPH to offer anticipatory management.
Children and adult patients with both CPSS and PoPH, as well as their close relatives (patient's parents and siblings) can take part in the study. Genetic variations within each family will be studied.
Study Design
- Study Type
- Observational
- Observational Model
- Family Based
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 1 Day to 99 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patient is a participant to the IRCPSS with history of PoPH
- •Trios composed of CPSS PoPH patients and their parents (trios are mandatory)
- •Brother/sister of an enrolled patient
- •Trios accept to provide biological samples (blood), sign the inform consent.
- •Siblings and/or siblings' legal representatives accept to provide biological samples (blood), sign the inform consent.
Exclusion Criteria
- •Trio condition is not met.
- •No genuine parent-offspring trios (check for medically assisted procreation with donors, and adoption)
- •For siblings, half-brothers or half-sisters are excluded, as well as adopted children, or children issued from medically assisted procreation with donors.
- •Secondary portosystemic shunts
- •The refusal by the patient or the patient's legal representatives to provide biological samples or agree with the proposed procedure or after voluntary withdrawal from the project.
- •The refusal of one of the parents to provide biological samples or to agree with the proposed procedure or after voluntary withdrawal from the project.
Outcomes
Primary Outcomes
List of variants from targeted analysis of selected gene panels
Time Frame: From February 2026 to February 2029
presence/absence of pathogenic variants in known genes (pulmonary arterial hypertension ; hereditary hemorrhagic telangiectasia ; congenital heart disease) and potentially pathogenic variants in genes previously associated with PoPH in cirrhosis cohort.
List of variants from whole genome analysis
Time Frame: Fron February 2026 to August 2029
variants identified using family based search for dominant or recessive potentially pathogenic variants
Secondary Outcomes
No secondary outcomes reported
Investigators
Prof. Valérie Mc Lin
Prof. Dr. Med.
University Hospital, Geneva